{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:35:53Z","timestamp":1787502953963,"version":"build-2736575974"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This article presents updated information on kratom (Mitragyna speciosa), a natural opioid with stimulant properties that is currently sold in the United States without a prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Kratom exerts opioid and alpha-2 agonistic effects, as well as anti-inflammatory and mild stimulant effects. Respiratory depression has not been commonly reported, but kratom does cause a host of adverse effects. While kratom may have a role in patients who are in chronic pain or dependent on opioid painkillers or heroin, this needs to be established in clinical trials. Kratom may have drug interactions as both a cytochrome P-450 system substrate and inhibitor. Kratom does not appear in normal drug screens and, especially when ingested with other substances of abuse, may not be recognized as an agent of harm. There are numerous cases of death in kratom users, but many involved polypharmaceutical ingestions. There are assessments where people have been unable to stop using kratom therapy and withdrawal signs\/symptoms occurred in patients or their newborn babies after kratom cessation. Both banning and failure to ban kratom places people at risk; a middle-ground alternative, placing it behind the pharmacy counter, might be useful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Kratom has a unique pharmacologic profile that might offer advantages over other opioids, but its high abuse liability, potential for drug interactions and adverse events, and inadequate research into the balance of benefits to harm are concerning. There is mounting information on the adverse events associated with kratom use and potential treatments that can be useful to clinicians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz221","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T09:53:35Z","timestamp":1571392415000},"page":"1915-1925","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacologic and clinical assessment of kratom: An update"],"prefix":"10.1093","volume":"76","author":[{"given":"C Michael","family":"White","sequence":"first","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, and Department of Pharmacy, Hartford Hospital, Hartford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"2019111315194314700_CIT0001","first-page":"e589","article-title":"Pharmacologic and clinical assessment of kratom","volume":"74","author":"White","year":"2017","journal-title":"Am J Health-Syst Pharm."},{"key":"2019111315194314700_CIT0002","author":"White"},{"key":"2019111315194314700_CIT0003","unstructured":"University of Hawaii. Rubiaceae. http:\/\/www.botany.hawaii.edu\/faculty\/carr\/rubi.htm (accessed 2016 Nov 11)."},{"key":"2019111315194314700_CIT0004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/19390211.2013.793541","article-title":"An evidence-based systematic review of kratom (Mitragyna speciosa) by the natural standard research collaboration.","volume":"10","author":"Ulbricht","year":"2013","journal-title":"J Diet Suppl."},{"key":"2019111315194314700_CIT0005","volume-title":"Dozens of congressmen ask DEA not to ban kratom next week","author":"Nelson"},{"key":"2019111315194314700_CIT0006","author":"Boodman"},{"key":"2019111315194314700_CIT0007","unstructured":"Brown M . States ban kratom supplement over abuse worries. US News & World Report., May 20, 2016. http:\/\/www.usnews.com\/news\/us\/articles\/2016-05-20\/states-ban-kratom-supplement-over-abuse-worries (accessed 2016 Nov 16)."},{"key":"2019111315194314700_CIT0008","doi-asserted-by":"crossref","first-page":"748","DOI":"10.15585\/mmwr.mm6529a4","article-title":"Notes from the field: kratom (Mitragyna speciosa) exposures reported to poison centers\u2014United States, 2010\u20132015","volume":"65","author":"Anwar","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2019111315194314700_CIT0009","unstructured":"Speciosa.org. Kratom legality map. http:\/\/speciosa.org\/home\/kratom-legality-map\/ (accessed 2019 Mar 11)."},{"key":"2019111315194314700_CIT0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.brainresbull.2016.05.004","article-title":"Traditional and non-traditional uses of mitragynine (kratom): a survey of the literature","volume":"126","author":"Singh","year":"2016","journal-title":"Brain Res Bull."},{"key":"2019111315194314700_CIT0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jep.2018.12.038","article-title":"Motives for using kratom (Mitragyna speciosa Korth.) among regular users in Malaysia","volume":"233","author":"Singh","year":"2019","journal-title":"J Ethnopharmacol."},{"key":"2019111315194314700_CIT0012","author":"MacLaren"},{"key":"2019111315194314700_CIT0013","first-page":"792","article-title":"Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects","volume":"112","author":"Prozialeck","year":"2012","journal-title":"J Am Osteopath Assoc."},{"key":"2019111315194314700_CIT0014","first-page":"1","article-title":"Kratom in Thailand: decriminalization and community control?","volume":"13","author":"Tanguay","year":"2011","journal-title":"Series Legislative Ref Drug Policy."},{"key":"2019111315194314700_CIT0015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1556-4029.2012.02207.x","article-title":"Identification of synthetic cannabinoids in herbal incense blends in the United States","volume":"57","author":"Logan","year":"2012","journal-title":"J Forensic Sci."},{"key":"2019111315194314700_CIT0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2017.03.007","article-title":"Patterns of kratom use and health impact in the US-results from an online survey","volume":"176","author":"Grundman","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"2019111315194314700_CIT0017","author":"National Institute on Drug Abuse"},{"key":"2019111315194314700_CIT0018","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neubiorev.2012.11.012","article-title":"From kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction","volume":"37","author":"Hassan","year":"2013","journal-title":"Neurosci Biobehav Rev."},{"key":"2019111315194314700_CIT0019","first-page":"21","article-title":"A study of kratom eaters in Thailand","volume":"27","author":"Suwanlert","year":"1975","journal-title":"Bull Narc."},{"key":"2019111315194314700_CIT0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13181-016-0588-y","article-title":"Suspected adulteration of commercial kratom products with 7-hydroxymitragynine","volume":"12","author":"Lydecker","year":"2016","journal-title":"J Med Toxicol."},{"key":"2019111315194314700_CIT0021","author":"Gottlieb"},{"key":"2019111315194314700_CIT0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2017.08.026","article-title":"The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse","volume":"134","author":"Kruegel","year":"2017","journal-title":"Neuropharmacology."},{"key":"2019111315194314700_CIT0023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-3-642-41199-1_22","article-title":"\u03b2-Arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia","volume":"219","author":"Raehal","year":"2014","journal-title":"Handb Exp Pharmacol."},{"key":"2019111315194314700_CIT0024","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2165\/11596830-000000000-00000","article-title":"Herbal medicines for the management of opioid addiction","volume":"25","author":"Ward","year":"2011","journal-title":"CNS Drugs."},{"key":"2019111315194314700_CIT0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Giovannitti","year":"2015","journal-title":"Anesth Prog."},{"key":"2019111315194314700_CIT0026","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00213-017-4813-4","article-title":"The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research","volume":"235","author":"Henningfield","year":"2018","journal-title":"Psychopharmacology (Berl)."},{"key":"2019111315194314700_CIT0027","doi-asserted-by":"crossref","first-page":"e115648","DOI":"10.1371\/journal.pone.0115648","article-title":"Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS One"},{"key":"2019111315194314700_CIT0028","first-page":"242","article-title":"Pharmacokinetics of mitragynine in man","volume":"9","author":"Trakulsrichai","year":"2015","journal-title":"Drug Des Devel Ther."},{"key":"2019111315194314700_CIT0029","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/00498254.2018.1552819","article-title":"Metabolic profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)","volume":"49","author":"Kamble","year":"2019","journal-title":"Xenobiotica."},{"key":"2019111315194314700_CIT0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin Proc."},{"key":"2019111315194314700_CIT0031","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jcph.266","article-title":"How MDMA\u2019s pharmacology and pharmacokinetics drive desired effects and harms","volume":"54","author":"White","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2019111315194314700_CIT0032","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jcph.742","article-title":"Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV): synthetic cathinones with serious health implications","volume":"56","author":"White","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"2019111315194314700_CIT0033","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00210-018-01605-y","article-title":"The inhibitory effects of mitragynine on P-glycoprotein in vitro","volume":"392","author":"Rusli","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2019111315194314700_CIT0034","author":"Family Practice Notebook"},{"key":"2019111315194314700_CIT0035","author":"Imodium (loperimide) package insert","year":"2016"},{"key":"2019111315194314700_CIT0036","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/ptr.5942","article-title":"PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids","volume":"31","author":"Manda","year":"2017","journal-title":"Phytother Res."},{"key":"2019111315194314700_CIT0037","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/02791072.2015.1096434","article-title":"Experiences of kratom users: a quantitative analysis","volume":"47","author":"Swogger","year":"2015","journal-title":"J Psychoactive Drugs."},{"key":"2019111315194314700_CIT0038","author":"ClinicalTrials.gov"},{"key":"2019111315194314700_CIT0039","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/10550490701525368","article-title":"Self-treatment of opioid withdrawal with a dietary supplement, kratom","volume":"16","author":"Boyer","year":"2007","journal-title":"Am J Addict."},{"key":"2019111315194314700_CIT0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/adb.12185","article-title":"Abuse potential and adverse cognitive effects of mitragynine (kratom)","volume":"21","author":"Yusoff","year":"2014","journal-title":"Addict Biol."},{"key":"2019111315194314700_CIT0041","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jep.2013.02.008","article-title":"Subchronic exposure to mitragynine, the principle alkaloid of Mitragyna speciosa, in rats","volume":"146","author":"Sabetghadam","year":"2013","journal-title":"J Ethnopharmacol."},{"key":"2019111315194314700_CIT0042","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.drugpo.2009.12.003","article-title":"The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy","volume":"21","author":"Vicknasingam","year":"2010","journal-title":"Int J Drug Policy."},{"key":"2019111315194314700_CIT0043","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/15563650.2019.1569236","article-title":"Kratom exposures reported to United States poison control centers: 2011\u20132017","volume":"57","author":"Post","year":"2019","journal-title":"Clin Toxicol (Phila)."},{"key":"2019111315194314700_CIT0044","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/phar.2280","article-title":"Kratom use and toxicities in the United States","volume":"39","author":"Eggleston","year":"2019","journal-title":"Pharmacotherapy."},{"key":"2019111315194314700_CIT0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ajem.2017.07.051","article-title":"Clinical outcomes after kratom exposures: a poison center case series","volume":"36","author":"Cumpston","year":"2018","journal-title":"Am J Emerg Med."},{"key":"2019111315194314700_CIT0046","author":"FDA"},{"key":"2019111315194314700_CIT0047","author":"FDA"},{"key":"2019111315194314700_CIT0048","author":"FDA"},{"key":"2019111315194314700_CIT0049","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550887.2013.854153","article-title":"Kratom exposures reported to Texas poison centers","volume":"32","author":"Forrester","year":"2013","journal-title":"J Addict Dis."},{"key":"2019111315194314700_CIT0050","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.forsciint.2014.10.025","article-title":"An accidental poisoning with mitragynine","volume":"245","author":"Karinen","year":"2014","journal-title":"Forensic Sci Int."},{"key":"2019111315194314700_CIT0051","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.forsciint.2016.12.020","article-title":"Mitragynine concentrations in two fatalities","volume":"271","author":"Domingo","year":"2017","journal-title":"Forensic Sci Int."},{"key":"2019111315194314700_CIT0052","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12024-018-0049-9","article-title":"Fatal combination of mitragynine and quetiapine \u2013 a case report with discussion of a potential herb-drug interaction","volume":"15","author":"Hughes","year":"2018","journal-title":"Forens Sci Med Pathol."},{"key":"2019111315194314700_CIT0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMc1811055","article-title":"Deaths in Colorado attributed to kratom","volume":"380","author":"Gershman","year":"2019","journal-title":"N Engl J Med."},{"key":"2019111315194314700_CIT0054","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s13181-010-0079-5","article-title":"Seizure and coma following kratom (Mitragynina [sic] speciosa Korth) exposure","volume":"6","author":"Nelsen","year":"2010","journal-title":"J Med Toxicol."},{"key":"2019111315194314700_CIT0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ebcr.2018.04.002","article-title":"Recurrent seizures from chronic kratom use, an atypical herbal opioid","volume":"10","author":"Tatum","year":"2018","journal-title":"Epilepsy Behav Case Rep."},{"key":"2019111315194314700_CIT0056","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1213\/XAA.0000000000000658","article-title":"Kratom, an emerging drug of abuse: a case report of overdose and management of withdrawal","volume":"10","author":"Diep","year":"2018","journal-title":"A A Pract."},{"key":"2019111315194314700_CIT0057","first-page":"1","article-title":"Kratom, an emerging drug of abuse, raises prolactin and causes secondary hypogonadism: case report","volume":"6","author":"LaBryer","year":"2018","journal-title":"J Investig Med High Impact Case Rep."},{"key":"2019111315194314700_CIT0058","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jep.2018.04.005","article-title":"Assessment of gonadotropins and testosterone hormone levels in regular Mitragyna speciosa (Korth.) users","volume":"221","author":"Singh","year":"2018","journal-title":"J Ethnopharmacol."},{"key":"2019111315194314700_CIT0059","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1634\/theoncologist.2017-0279","article-title":"The harm in kratom","volume":"22","author":"Drago","year":"2017","journal-title":"Oncologist."},{"key":"2019111315194314700_CIT0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/20009666.2018.1468693","article-title":"Kratom, a dangerous player in the opioid crisis","volume":"8","author":"Tayabali","year":"2018","journal-title":"J Community Hosp Int Med Perspect."},{"key":"2019111315194314700_CIT0061","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/gr990e","article-title":"Histologic characterization of kratom use-associated liver injury","volume":"11","author":"Riverso","year":"2018","journal-title":"Gasteroenterol Res."},{"key":"2019111315194314700_CIT0062","doi-asserted-by":"crossref","first-page":"e550","DOI":"10.1097\/MJT.0000000000000631","article-title":"N-Acetylcysteine for acute hepatitis induced by kratom herbal tea","volume":"25","author":"Mousa","year":"2018","journal-title":"Am J Ther."},{"key":"2019111315194314700_CIT0063","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1097\/MJT.0000000000000802","article-title":"Herb-induced liver injury with cholestasis and renal injury secondary to short-term use of kratom (Mitragyna speciosa)","volume":"26","author":"Antony","year":"2018","journal-title":"Am J Ther."},{"key":"2019111315194314700_CIT0064","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.japh.2018.05.006","article-title":"Possible kratom-induced hepatomegaly: a case report","volume":"58","author":"Griffiths","year":"2018","journal-title":"J Am Pharm Assoc."},{"key":"2019111315194314700_CIT0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/02791072.2018.1562591","article-title":"Legally lethal kratom: a herbal supplement with overdose potential","volume":"51","author":"Shekar","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"2019111315194314700_CIT0066","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/08998280.2017.11929647","article-title":"Posterior reversible leukoencephalopathy syndrome after kratom ingestion","volume":"30","author":"Castillo","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)."},{"key":"2019111315194314700_CIT0067","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/jat\/bky028","article-title":"Suspected driving under the influence case involving mitragynine","volume":"42","author":"Wright","year":"2018","journal-title":"J Anal Toxicol."},{"key":"2019111315194314700_CIT0068","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/02791072.2018.1555345","article-title":"Long-term cognitive effects of kratom (mitragyna speciose Korth) use","volume":"51","author":"Singh","year":"2018","journal-title":"J Psychoactive Drugs."},{"key":"2019111315194314700_CIT0069","author":"FDA"},{"key":"2019111315194314700_CIT0070","author":"FDA"},{"key":"2019111315194314700_CIT0071","author":"FDA"},{"key":"2019111315194314700_CIT0072","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jen.2017.03.016","article-title":"Introducing\u2026 kratom","volume":"43","author":"Pizarro-Osilla","year":"2017","journal-title":"J Emerg Nurs."},{"key":"2019111315194314700_CIT0073","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/NPM-1863","article-title":"Natural drugs, not so natural effects: neonatal abstinence syndrome secondary to kratom","volume":"12","author":"Davidson","year":"2018","journal-title":"J Neonatal Perinatal Med."},{"key":"2019111315194314700_CIT0074","doi-asserted-by":"crossref","first-page":"e20181839","DOI":"10.1542\/peds.2018-1839","article-title":"Neonatal abstinence syndrome due to maternal kratom use","volume":"142","author":"Eldridge","year":"2018","journal-title":"Pediatrics."},{"key":"2019111315194314700_CIT0075","first-page":"121","article-title":"Novel case of maternal and neonatal kratom dependence and withdrawal","volume":"64","author":"Mackay","year":"2018","journal-title":"Can Fam Physician."},{"key":"2019111315194314700_CIT0076","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/pch\/pxy084","article-title":"An unusual cause for neonatal abstinence syndrome","volume":"24","author":"Murthy","year":"2019","journal-title":"Paediat Child Health."},{"key":"2019111315194314700_CIT0077","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/AOG.0000000000002871","article-title":"Use of kratom, an opioid-like traditional herb, in pregnancy","volume":"132","author":"Smid","year":"2018","journal-title":"Obstet Gynecol."},{"key":"2019111315194314700_CIT0078","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2014.03.017","article-title":"Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users","volume":"139","author":"Singh","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"2019111315194314700_CIT0079","first-page":"125","article-title":"Social functioning of kratom (Mitragyna speciosa) users in Malaysia","volume":"201547","author":"Singh","journal-title":"J Psychoactive Drugs"},{"key":"2019111315194314700_CIT0080","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/02791072.2018.1443234","article-title":"Severity of pain and sleep problems during kratom (Mitragyna speciosa Korth.) cessation among regular kratom users","volume":"50","author":"Singh","year":"2018","journal-title":"J Psychoactive Drugs."},{"key":"2019111315194314700_CIT0081","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/02791072.2018.1511879","article-title":"Severity of kratom (Mitragyna speciosa Korth.) psychological withdrawals symptoms","volume":"50","author":"Singh","year":"2018","journal-title":"J Psychoactive Drugs."},{"key":"2019111315194314700_CIT0082","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1213\/01.ane.0000287675.15225.0b","article-title":"Mechanisms of morphine enhancement of spontaneous seizure activity","volume":"105","author":"Saboory","year":"2007","journal-title":"Anesth Analg."},{"key":"2019111315194314700_CIT0083","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.annemergmed.2016.03.047","article-title":"Loperamide abuse associated with cardiac dysrhythmia and death","volume":"69","author":"Eggleston","year":"2017","journal-title":"Ann Emerg Med."},{"key":"2019111315194314700_CIT0084","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","article-title":"QTc interval screening in methadone treatment","volume":"150","author":"Krantz","year":"2009","journal-title":"Ann Intern Med."},{"key":"2019111315194314700_CIT0085","author":"Funk"},{"key":"2019111315194314700_CIT0086","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1751143717712652","article-title":"Death from kratom toxicity and the possible role of intralipid","volume":"19","author":"Aggarwal","year":"2018","journal-title":"J Intensive Care Soc."},{"key":"2019111315194314700_CIT0087","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/02791072.2018.1562133","article-title":"Kratom withdrawal: a systematic review with case series","volume":"51","author":"Stanciu","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"2019111315194314700_CIT0088","first-page":"49","article-title":"A case report of kratom addiction and withdrawal","volume":"115","author":"Galbis-Reig","year":"2016","journal-title":"WMJ."},{"key":"2019111315194314700_CIT0089","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/ADM.0000000000000435","article-title":"Treatment of kratom withdrawal and addiction with buprenorphine","volume":"12","author":"Khazaeli","year":"2018","journal-title":"J Addict Med."},{"key":"2019111315194314700_CIT0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000000428","article-title":"Treatment of kratom dependence with buprenorphine-naloxone maintenance","volume":"12","author":"Buresh","year":"2018","journal-title":"J Addict Med."},{"key":"2019111315194314700_CIT0091","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000320288","article-title":"A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence","volume":"16","author":"McWhiten","year":"2010","journal-title":"Eur Addict Res."},{"key":"2019111315194314700_CIT0092","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0924-9338(11)71761-8","article-title":"P01-50-Kratom and alcohol dependence: clinical symptoms, withdrawal treatment and pharmacological mechanism\u2013a case report","volume":"26","author":"Havemann-Reincke","year":"2011","journal-title":"Eur Psychiatry."},{"key":"2019111315194314700_CIT0093","author":"FDA"},{"key":"2019111315194314700_CIT0094","author":"National Institute of Drug Abuse"},{"key":"2019111315194314700_CIT0095","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jcph.1449","article-title":"Loperamide: a readily available but dangerous opioid substitute","volume":"59","author":"White","year":"2019","journal-title":"J Clin Pharmacol."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/23\/1915\/30696438\/zxz221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/23\/1915\/30696438\/zxz221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:12:41Z","timestamp":1695316361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/23\/1915\/5593614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":95,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2019,10,18]]},"published-print":{"date-parts":[[2019,11,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz221","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,10,18]]}}}